An investigation of the α1A-adrenergic receptor gene and antipsychotic-induced side-effects

Human Psychopharmacology

Volumn 23, Issue 2, 2008, Pages 107-114

  Saiz, Pilar A ^a,b   Susce, Margaret T ^c   Clark, Dan A ^a   Kerwin, Robert W ^a   Molero, Patricio ^a,d   Arranz, Maria J ^a   de Leon, Jose ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Eastern State Hospital   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

2a1'A adrenergic receptor; Genetic association; Risperidone; Side effects

Indexed keywords

ADENINE; ALPHA 1A ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CYTOSINE; GUANINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THYMINE; ZIPRASIDONE; ADRENERGIC RECEPTOR ALPHA(1A); ALPHA 1 ADRENERGIC RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIPOLAR DISORDER; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA; UNITED STATES; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG EFFECT; DYSKINESIA; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DYSKINESIA, DRUG-INDUCED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 40549107457     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.903     Document Type: Article

References (45)

1. Bakker PR, van Harten PN, Van Os J. 2006. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 83(2-3): 185-192.
2. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. 2001. Genetic dissection of atypical antipsychoti-c-induced weight gain: novel preliminary data on the pharmaco-genetic puzzle. J Clin Psychiatry 62(Suppl 23): 45-66.
3. Bolonna AA, Arranz MJ, Munro J, et al. 2000. No influence of adrenergic receptor polymorphisms on schizophrenia and anti-psychotic response. Neurosci Lett 280: 65-68.
4. Buckley PF. 2001. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50(11): 912-924.
5. Cahir M, Mawhinney T, King DJ. 2004. Differential region-specific regulation of central alpha 1-adrenoceptor binding following chronic haloperidol and clozapine administration in the rat. Psychopharmacology (Berl) 172(2): 196-201.
6. Clark DA, Arranz MJ, Mata I, Lopez-Ilundain J, Perez-Nievas F, Kerwin RW. 2005. Polymorphisms in the promoter region of the alpha 1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biol Psychiatry 58(6): 435-439.
7. Clark DA, Mancama D, Kerwin RW, Arranz MJ. 2006. Expression of the alpha IA-adrenergic receptor in schizophrenia. Neurosci Lett 401(3): 248-251.
8. Correll CU, Malhotra AK. 2004. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 174(4): 477-489.
9. Curtis D, Knight J. Sham PC. 2006. Program report: GENECOUNTING support programs. Ann Hum Genet 70(Pt 2): 277-279.
10. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. 2005a. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66(1): 15-27.
11. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. 2005b. Polymorphic variations in GSTMI, GSTTI, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychapharmacal 25(5): 448-456.
12. Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S. 2002. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 12(1): 55-58.
13. Fajardo N, Deshaies Y. 1998. Long-term alpha I-adrenergic blockade attenuates diet-induced dyslipidernia and hyperinsulinemia in the rat. J Cardiovasc Pharmacol 32(6): 913-919.
14. Graham RM. 1989. Selective alpha I-adrenergic blockade, lipids, and coronary heart disease risk. Considerations in the treatment of mild hypertension. Am J Med 87(2A): 53S-56S.
15. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology Washington.
16. Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G. 2003. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 13(3): 163-168.
17. Ipsen M, Zhang Y, Dragsted N, Han C, Mulvany MJ. 1997. The antipsychotic drug sertindole is a specific inhibitor of alpha IA-adrenoceptors in rat mesenteric small arteries. Eur J Pharmacol 336(1): 29-35.
18. Itskovitz HD. 1994. Alpha I -blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 16(3): 490-504.
19. Kane JM. 1999. Management strategies for the treatment of schizophrenia. J Clin Psychiatry 60(Suppl 12): 13-17.
20. Lakka HM, Laaksonen DE, Lakka TA, et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21): 2709-2716.
21. Lamberti JS, Olson D, Crilly JF, et al. 2006. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163(7): 1273-1276.
22. Lerer B, Segman RH, Fangerau H, et al. 2002. Pharmacogenetics of tardive dyskinesia. Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27(1): 105-119.
23. Lerer B, Segman RH, Tan EC, et al. 2005. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tattlive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 8(3): 411-425.
24. Leysen JE. 2000. Receptor profile of antipsychotics. In Atypical antipsychotics, BA, Ellenbroek AR Cools (eds.), Bikhäuser Verlag: Basel/Switzerland; 57-81.
25. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1-100.
26. Ma J, Ye N, Cohen BM. 2006. Expression of noradrenergic alpha1, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 30(4): 647-657.
27. Morgenstern H, Glazer WM. 1993. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 50(9): 723-733.
28. Muller DJ, Shinkai T, De LV, Kennedy JL. 2004. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 4(2): 77-87.
29. Nakazono Y, Abe H, Murakami H, et al. 2005. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients. Int J Clin Pharmacol Ther 43(4): 163-171.
30. Ohmori 0, Shinkai T, Hori H, Matsumoto C, Nakamura J. 2003. A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy. Prog Neuropsychopharmacol Biol Psychiatry 27(4): 581-586.
31. Olfson M, Blanco C, Liu L, Moreno C, Laje G. 2006. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63(6): 679-685.
32. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP. 2005. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 15(3); 151-158.
33. Reja V, Goodchild AK, Pilowsky PM. 2002. Catecholamine-related gene expression correlates with blood pressures in SHR. Hypertension 40(3): 342-347.
34. Reynolds GP, Zhang ZJ, Zhang XB. 2002. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359(9323): 2086-2087.
35. Reynolds GP, Zhang Z, Zhang X. 2003. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 160(4): 677-679.
36. Schillevoort I, de Boer A, van der WJ, et al. 2002. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 12(3): 235-240.
37. Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39(4): 486-487.
38. Scordo MG, Spina E, Romeo P, et al. 2000. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 56(9-10): 679-683.
39. Segman RH, Lerer B. 2002. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry 7(2): 137-139.
40. Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, Tsujimoto G. 1996. Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy 1. Br J Pharmacol 118(6): 1403-1408.
41. Susce MT, Villanueva N, Diaz FJ, de Leon J. 2005. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 66(2): 167-173.
42. Svensson TH. 2003. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27(7): 1145-1158.
43. Templeman LA, Reynolds GP, Arranz B, San L. 2005. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15(4): 195-200.
44. Tsai SJ, Hong CJ, Yu YW, Lin CH. 2002. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 360(9347): 1790.
45. Xie HG, Kim RB, Stein CM, Gainer JV, Brown NJ, Wood AJ. 1999. Alpha1A-adrenergic receptor polymorphism; association with ethnicity but not essential hypertension. Pharmacogenetics 9(5): 651-656.